^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGFR2 (Fibroblast growth factor receptor 2)

    i
    Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
    19d
    FGFR2b in Gastric Cancer: Translating a Therapeutic Target into a Reliable Biomarker. (PubMed, Cancers (Basel))
    As FGFR2b-directed strategies move forward, their success will depend not only on drug efficacy, but also on standardized testing, careful reporting, and selective reassessment when disease biology changes. FGFR2b therefore offers a useful model for how protein biomarkers can be developed in gastric cancer: not as isolated positive-or-negative labels, but as clinically interpreted variables within a changing therapeutic landscape.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18)
    19d
    The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer. (PubMed, Cancers (Basel))
    We evaluate the expanding clinical trial landscape of immunotherapy in CCA and more broadly in BTC, including adoptive cell therapies and cancer vaccines. Together, these advances position CCA as a paradigm of how tumor genotype and microenvironment co-evolve to define immunotherapy sensitivity and resistance.
    Review • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MTAP (Methylthioadenosine Phosphorylase)
    |
    KRAS mutation • IDH1 mutation • FGFR2 mutation • FGFR2 fusion
    19d
    Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer. (PubMed, Clin Cancer Res)
    This comprehensive molecular profiling study illustrates the real-world utility and limitations of targeted next-generation sequencing of BTC and affirms the use of precision medicine in patients with these diseases. Characterization of genomic heterogeneity and therapeutic resistance has the potential to inform ongoing drug development efforts for BTC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • MDM2 (E3 ubiquitin protein ligase) • SMAD4 (SMAD family member 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET amplification • MTAP deletion
    19d
    The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic Cholangiocarcinoma. (PubMed, Ann Surg Oncol)
    Neoadjuvant therapy was associated with improved PROS for resected iCCA patients, consistent with a potential role in biologic selection. Recipients of NAT showed enriched targetable molecular alterations and better PROS despite stable recurrence patterns. These findings position PROS as a relevant endpoint in NAT-treated iCCA, complementing conventional survival metrics.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    20d
    Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment-A Case Report. (PubMed, Curr Oncol)
    This case highlights the importance of early recognition of cutaneous lesions in patients on FGFR inhibitors. Prompt cessation of therapy, management of metabolic derangements, and consideration of sodium thiosulfate may be lifesaving.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    Pemazyre (pemigatinib)
    21d
    A working model for CCN3 C-terminal domain-mediated transcriptional modulation of the plasminogen activation system. (PubMed, J Cell Commun Signal)
    In this manuscript, we propose an exploratory integrative model that brings together previously unassociated observations into a coherent framework. In this model, the C-terminal module, present in all CCN proteins except CCN5, is proposed to direct the formation of homo- and heterodimers, which constitute a fundamental level of transcriptional regulation.
    Review • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
    22d
    Molecular Glues Recruiting RNF213 As an E3 Ligase for Targeted Protein Degradation: A Minimal Dibromoacetamide Warhead As a Recruitment Ligand. (PubMed, J Am Chem Soc)
    We developed CYB-5067 by equipping the pan-FGFR inhibitor Infigratinib with a minimal dibromoacetamide covalent warhead...Our work identifies RNF213 as an exploitable ligase for TPD and establishes covalent molecular glues as a modular platform. This strategy expands the scope of degrader design beyond conventional E3 ligases, offering an avenue for developing potent and selective therapeutics.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • CDK12 (Cyclin dependent kinase 12) • CRBN (Cereblon)
    |
    Truseltiq (infigratinib)
    22d
    Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial. (PubMed, Br J Cancer)
    The findings support continued investigation of FGFR-targeted strategies in FGFR2-amplified GC/GEJ adenocarcinoma, while underscoring the need for larger studies, refined biomarker selection, and deeper characterization of resistance mechanisms.
    P2 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    Truseltiq (infigratinib)
    23d
    From progression to complete remission - a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma. (PubMed, Klin Onkol)
    This case demonstrates the significant therapeutic potential of pemigatinib in a patient with metastatic cholangiocarcinoma with FGFR2 fusion, where complete disease remission was achieved after previous progression on standard treatment.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • BICC1 (BicC Family RNA Binding Protein 1)
    |
    FGFR2 fusion • FGFR fusion
    |
    Pemazyre (pemigatinib)
    23d
    A Hypoxia and Immune Escape-Related Gene Signature for the Diagnosis of Prostate Cancer: An Integrated Bioinformatics Study. (PubMed, Int J Med Sci)
    Exploratory grouping by the model-derived RiskScore revealed differences in pathway and immune infiltration patterns, suggesting an association between the signature and intratumoral molecular heterogeneity. These exploratory findings primarily serve to characterize the biological features related to the model and provide supplementary clues for understanding molecular alterations in prostate cancer; they should be interpreted with caution.
    Journal • Gene Signature
    |
    FGFR2 (Fibroblast growth factor receptor 2) • GDF15 (Growth differentiation factor 15) • NCAM1 (Neural cell adhesion molecule 1) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • SLC7A11 (Solute Carrier Family 7 Member 11) • RBMS3 (RNA Binding Motif Single Stranded Interacting Protein 3)
    23d
    Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort. (PubMed, Eur J Cancer)
    Clinical activity of FGFRi was heterogenous across FGFR alteration and tumor types. FGFR fusions and mutations were associated with greater benefit, whereas amplifications were not. Further investigation of resistance mechanisms and development of next-generation FGFRi are needed.
    Retrospective data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR2 fusion • FGFR mutation • FGFR fusion
    1m
    Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer. (PubMed, Cancer Med)
    We demonstrated the real-world genomic characteristics of BTC patients, which may have promising implications for the development and application of precision medicine in the future. Well-designed prospective studies are mandatory to validate the predictive role of significant genomic alterations observed in our study.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • LRP1B (LDL Receptor Related Protein 1B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • MSH3 (MutS Homolog 3)